tirzepatide glucagon Major physiological roles of GLP-1 and GIP. is acting as an... Twincretin drug Tirzepatide shows unmatched

Description

1 Dose strength Rybelsus: lowmoderate daily doses for glucose control Oral Wegovy: much higher daily dose to match injectable Wegovy exposure With oral bioavailability at ~1%, obesity efficacy simply requires more drug not interchangeable

The liver data may be even more important for employers

It's a question physicians are being asked regularly these days.

Group one included patients with moderate PAD who were started on GLP-1 RAs, and group two included patients with moderate PAD who were not started on GLP-1 RAs. At one year, patients with moderate PAD who were started on GLP-1 RAs had fewer major adverse limb events (MALE) (0.8% vs 1.5%), major adverse cardiac events (MACE) (25.4% vs 29.3%), and decreased risk of hospitalizations (17.9 vs 26.8%)